EP0579650A1 - Nouveaux composes - Google Patents

Nouveaux composes

Info

Publication number
EP0579650A1
EP0579650A1 EP92907701A EP92907701A EP0579650A1 EP 0579650 A1 EP0579650 A1 EP 0579650A1 EP 92907701 A EP92907701 A EP 92907701A EP 92907701 A EP92907701 A EP 92907701A EP 0579650 A1 EP0579650 A1 EP 0579650A1
Authority
EP
European Patent Office
Prior art keywords
formula
compound
compound according
hydrogen
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP92907701A
Other languages
German (de)
English (en)
Inventor
Roger Edward Smithkline Beecham Markwell
Robert William Smithkline Beecham Ward
Shahzad Sharooq Smithkline Beecham Rahman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of EP0579650A1 publication Critical patent/EP0579650A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
    • C07D245/02—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Definitions

  • the present invention relates to novel hydroxamic acids, processes for their preparation and their use in medicine.
  • the present invention relates to their use as inhibitors of enzymes of the collagenase family of neutral metalloproteases, for treating arthritic and other diseases.
  • the mammalian collagenase family of enzymes comprises a number of proteases, exemplified by interstitial (type I) collagenase itself, the stromelysins (also known as proteoglycanases or transins) , fibroblast and polymorphonuclear leucocyte gelatinases (also known as collagen-IV-ases) , and 'pump-1' (putative metalloprotease 1, uterine metalloprotease) [Goldberg et al, J. Biol. Chem.
  • inhibitors of the collagenase family of enzymes such as are disclosed in the present invention
  • chronic arthritic diseases leading to extensive loss of the collagen, proteoglycan and elastin components of the cartilage, bone and tendons within the joints should be amenable to treatment with inhibitors of the collagenases, proteoglycanases (stromelysins) and gelatinases currently thought to be the major enzymes involved.
  • These enzymes have been detected in extracts of synovial an cartilage tissue, and have also been extensively studied in tissue cultures of a wide range of connective tissues.
  • inhibitors such as the Tissue Inhibitor of Metalloproteases and alpha-2 macroglobulin.
  • a imbalance between the local levels of the proteolytic enzym and natural inhibitors will allow destruction of connective tissue components to occur.
  • the compounds described in the present invention being synthetic and low molecular weight inhibitors of this famil of enzymes, offer a therapeutically useful way in which a more normal or non-pathological balance between inhibition and enzymic activity can be restored: they thus act to complement and supplement the endogenous enzyme inhibitors. Indeed, because these enzymes usually act only within restricted pericell ⁇ lar environments, before being inactivated by inhibitors circulating in the blood and present in most inflammatory exudates, the low molecular weight inhibitors disclosed here may be more effective than endogenous proteinaceous inhibitors that are excluded by their size from the localized regions of connective tissue destruction.
  • R]_ is hydrogen, C ⁇ -galkyl, or -(CH2) n -A-R where n is from to 6, A is a bond or an oxygen or sulphur heteroatom and R is an optionally substituted aryl or optionally substitute heteroaryl group;
  • R2 is C3_galkyl
  • R3 is - (CH2)p-X- (CH2)q- where p is an integer from 1 to 9, is an integer from 2 to 10, and the moiety -(CH2)p- is adjacent to the carbon atom marked with an asterisk in formula (1), and X is -NR5- where R5 is selected from hydrogen, C ⁇ -g alkyl, C2- alkanoyl, C]__g alkoxycarbonyl a aryl, aralkyl or aralkyloxycarbonyl in each of which the a moiety is optionally substituted.
  • each alkyl or alkoxy group is CI- Q group, more preferably a C ⁇ _g group, and may be strai chain or branched.
  • aryl groups include naphthyl and phenyl, preferably phenyl.
  • Heteroaryl groups include thienyl, fur and pyridyl.
  • Optional substituents for aryl and heteroaryl groups will b apparent to those skilled in the art and may be selected fr -OH, C ⁇ _galkyl, C ⁇ _galkoxy and halogen.
  • R ⁇ include hydrogen; C ⁇ - ⁇ alkyl; and (CH2) n _A-R 4 where n is 1, A is a bond or sulphur atom and R is an aryl or heteroaryl group.
  • R]_ is hydrogen or methyl.
  • R2 is preferably a C4 alkyl group, most preferred are C4alk groups such as n-butyl, iso-butyl or sec-butyl, especially iso-butyl.
  • R3 include - (CH2) p -X-(CH2)q- wherein p and q hav values such that R3 forms part of an 11- to 16-membered azalactam structure, and X is a group -NR5- where R5 is hydrogen, methyl, benzyl, t-butoxycarbonyl or benzyloxycarbonyl.
  • R3 is -(CH2) p - - (CH2)q- where p is 4 and q is 5, or p is 4 and q is 6 and X is -NR5 where R5 is hydrogen.
  • the compounds of formula (1) may form salts with bases e.g. sodium hydroxide.
  • bases e.g. sodium hydroxide.
  • t compounds of formula (1) may form acid addition salts e.g. with hydrochloric acid. Such compounds form part of the present invention.
  • the compounds of formula (1) have at least three asymmetric centres and therefore exist in more than one stereoisomeric form.
  • the invention extends to all such forms and to mixtures thereof, including racemates, and diastereoisomeric mixtures.
  • Preferred isomers are those having the (S)-configuration at the chiral centre marked with an asterisk in formula (1) .
  • the present invention provides the compounds of formula (1) or pharmaceutically acceptable salts thereof for use as active therapeutic agents, particularly as agents for treatment of musculo-skeletal disorders resulting from collagenolytic activity, particularly arthritic diseases, and tissue remodelling.
  • Compounds of formula (1) also have potential utility in the treatment of cancer; for preventing myelin degradation in th central and peripheral nervous system; and in other conditions in which members of the collagenase family of neutral metalloproteases have pathological or other roles.
  • the present invention also provides a process for the preparation of a compound of formula (1) , which process comprises :
  • R is an O-protecting group and R ⁇ , R2 and R3 are as hereinbefore defined;
  • Rl, R2 and R3 are as hereinbefore defined with hydroxylam or a salt thereof;
  • step (c) optionally after step (a) or step (b) converting compound of the formula (1) into another compound of the formula (1) .
  • R in a compound of the formula (2) is benzyl or a substituted benzyl group, preferably R is benzyl.
  • Cleavag of the group R may be carried out by standard deprotection procedures known in the art, including hydrogenolysis.
  • a compound of the formula (2) in which R is benz or substituted benzyl is hydrogenated in the presence of a metal catalyst such as palladium on charcoal in a suitable organic solvent such as a C ⁇ _4alcohol at ambient or elevat (e.g. 20-60°C) temperature.
  • a metal catalyst such as palladium on charcoal
  • a suitable organic solvent such as a C ⁇ _4alcohol at ambient or elevat (e.g. 20-60°C) temperature.
  • a compound of the formula (1) may be prepared by reacting compound of the formula (3) with hydroxylamine or a salt thereof using standard coupling techniques.
  • a compound of the formula (3) may be reacted with a coupling reagent such as ethyl chloroformate or l-ethyl-3-[3- (dimethylamino)-propyl]carbodiimide hydrochloride (EDC) in the presence of l-hydroxybenzotriazole in a suitable solven such as dichloromethane, followed by reaction with hydroxylamine or a salt thereof, for example hydroxylamine hydrochloride.
  • a coupling reagent such as ethyl chloroformate or l-ethyl-3-[3- (dimethylamino)-propyl]carbodiimide hydrochloride (EDC)
  • EDC dimethylamino)-propyl]carbodiimide hydrochloride
  • a compound of the formula (2) may be prepared by coupling, for example by conventional coupling techniques, a compound of the formula (3) with an O-protected hydroxylamine, for example benzylhydroxylamine.
  • a compound of the formula (3) may be treated with a standard coupling agent such as EDC/1-hydroxybenzotriazole or 1,3-dicyclohexyl- carbodiimide/1-hydroxybenzotriazole in a suitable inert solvent such as dichloromethane or acetonitrile in the presence of a base such as triethylamine or diisopropyl- ethylamine followed by addition of benzylhydroxylamine or a salt thereof.
  • a standard coupling agent such as EDC/1-hydroxybenzotriazole or 1,3-dicyclohexyl- carbodiimide/1-hydroxybenzotriazole
  • a suitable inert solvent such as dichloromethane or acetonitrile
  • a base such as triethyl
  • R l' R 2 anc R 3 are as hereinbefore defined and Rg is an ester forming group.
  • Rg in a compound of the formula (4) is C]__galkyl especially methyl or an optionally substituted benzyl gro
  • a compound of the formula (4) is hydrolysed by reaction with an aqueous base such as sodium hydroxide or potassium hydroxide optionally in a co-solvent such as a C ⁇ _ alcohol or 1,4 dioxane at ambient temperature.
  • an aqueous base such as sodium hydroxide or potassium hydroxide
  • a co-solvent such as a C ⁇ _ alcohol or 1,4 dioxane at ambient temperature.
  • a compound of the formula (3) in which R ⁇ is -(CH2) n -A-R where n is 1, and A is oxygen or sulphur and is as hereinbefore defined may be prepared by reacting a compound of the formula (5) :
  • R2 and R3 are as hereinbefore defined with the appropriate thiol or phenol, R4-A-H in which A is oxygen or sulphur an R4 is as hereinbefore defined.
  • a compound of the formula (5) is reacted with a thiol or phenol optionally in the presence of an organic solvent such as toluene at ambient or elevated temperature (e.g. 40-100°C) , preferably at 60°C.
  • an organic solvent such as toluene at ambient or elevated temperature (e.g. 40-100°C) , preferably at 60°C.
  • a compound of the formula (5) may be prepared from a compo of the formula (6) :
  • R2 and R3 are as hereinbefore defined, R7 is a C]__galkyl o an optionally substituted benzyl group, and Rg is a C ⁇ _galkoxycarbonyl or benzyloxycarbonyl group.
  • a compound of the formula (6) in which R7 is optionally substituted benzyl and Rg is benzyloxycarbonyl be hydrogenated to the corresponding malonic acid, derivative, which is then treated with aqueous formaldehyde and piperidine to give a compound of the formula (5) as hereinbefore defined.
  • a compound of the formula (6) may be prepared by a procedur similar to that outlined in PCT/GB89/01398.
  • a compound of the formula (4) may be prepared by coupling a acid of the formula (7) :
  • R3 is as hereinbefore defined.
  • a compound of the formula (7) is converted to its corresponding acid chlorid using a standard chlorinating agent, such as thionyl chlor or oxalyl chloride, optionally in an organic solvent such dichloromethane at ambient or reduced temperature (e.g. -1 to 0°C) followed by addition of an amine of the formula (8)
  • R5 in R3 is hydrogen
  • the secondary amine is suitabl in protected form, for example as a benzyloxycarbonyl derivative.
  • reaction may be carried out in the presence of a coupling agent, such as dicyclohexyl- carbodiimide or l-ethyl-3-[3-(dimethylamino)propyl]- carbodiimide hydrochloride in the presence of 1-hydroxy- benzotriazole, or using 1,1'-carbonyldiimidazole, in an in solvent such as dichloromethane or acetonitrile.
  • a coupling agent such as dicyclohexyl- carbodiimide or l-ethyl-3-[3-(dimethylamino)propyl]- carbodiimide hydrochloride
  • 1-hydroxy- benzotriazole or using 1,1'-carbonyldiimidazole, in an in solvent such as dichloromethane or acetonitrile.
  • Y is nitrogen protection group
  • Z is R5, to give the corresponding aldehyde, followed by removal of Z when R5 is an acyl group; cyclisation and reduction; and thereafter, a necessary, removing the nitrogen protection group Y and interconverting R5.
  • Suitable values for Y include t-butoxycarbonyl (BOC) and benzyloxycarbonyl groups, preferably t-butoxycarbonyl.
  • the oxidation may be carried out using pyridinium chlorochromate or under Swern oxidising conditions, for example by treatment with di ethylsulphoxide and an acyl halide followed by triethylamine, as described by D. Swern al., J. Org. Chem., 43, 2480 (1978) .
  • the cyclisation and reduction step may be effected by catalytic hydrogenation over a suitable noble metal catalyst, for example palladium on carbon, or by reaction with sodium cyanoborohydride or sodium borohydride. In some cases the yield of azalactams may be increased by carrying out the reductive amination ste under acidic conditions.
  • Nitrogen protection groups may be removed by standard methods.
  • a Y or Z t-butoxycarbonyl group may be removed by treatment with trifluoroacetic acid at reduced temperature.
  • a Y or Z benzyloxycarbonyl group may be removed by conventional hydrogenation over palladium on carbon, or by treatment with formic acid-methanol and palladium black.
  • group Z may be selected to undergo concomitant cleavage during the cyclisation reaction to give a compound in whic R5 is hydrogen.
  • Z is a benzyloxycarbony group, it will be readily removed by catalytic hydrogenati
  • An R5 hydrogen may be interconverted to an R5 C ⁇ -g alkyl, aralkyl or aryl group.
  • the secondary amine group may be alkylated, to form an R5 alkyl group.
  • the ami group may be methylated to form an R5 methyl group.
  • the methylation step may be effected by catalytic hydrogenation over a suitable noble metal catalyst, for example palladium on carbon, in the presence of aqueous formaldehyde.
  • reaction may be carried out using standard procedures f forming an amide from a carboxylic acid and an amine, for example using a coupling agent such as 1, 1'-carbonyl- diimidazole, 1,3-dicyclohexyl-carbodiimide or l-ethyl-3-[3- (dimethylamino)propyl]carbodiimide hydrochloride in the presence of l-hydroxybenzotriazole.
  • a coupling agent such as 1, 1'-carbonyl- diimidazole, 1,3-dicyclohexyl-carbodiimide or l-ethyl-3-[3- (dimethylamino)propyl]carbodiimide hydrochloride in the presence of l-hydroxybenzotriazole.
  • Compounds of formula (10) are di-aminoalkanoic acid derivatives. These are known compounds or may be prepared from known starting materials by standard methods.
  • the compound of formula (8) in which R3 is - (CH2) p -X- (CH2)q- where p is 3, q is 3 to 8 and X is -NH- is prepared from a compound of formula (10) derived from ornithine which is commercially available.
  • the compound of formula (8) in which R3 is - (CH2)p-X- (CH2)q- where p is 4, q is 3 to 8 and X is -NH- is prepared from a compound of formula (10) derived from the amino acid lysine.
  • the amino alcohols of formula (11) are known compounds.
  • a compound of the formula (7) in which R ⁇ is a methyl grou may be prepared from a compound of the formula (12) :
  • R ⁇ is a methyl group
  • R2 and Rg are as hereinbefo defined and R9 is an ester forming group.
  • a compound of the formula (12) is treated with an acid, such as trifluoroacetic acid, at ambient or reduced temperature (e.g. -5 to 0°C) .
  • an acid such as trifluoroacetic acid
  • Rg and R9 are chosen so that R9 is selectively cleaved in the presence of acid producing a compound of the formula (7) in which Rg is retained.
  • R9 is a t-butyl group.
  • a compound of the formula (12) in which R ] _ is methyl may be prepared from a compound of the formula (13) :
  • a compound of formula (13) is treated with an alcohol RgOH in the presence of an acid catalyst in an alcohol solvent at elevated temperature, for example at the reflux temperature of the reaction mixture followed by hydrogenation in the presence of a noble metal catalyst.
  • a compound of formula (12) in which R ] _ and Rg are methyl may be prepared by treating a compound of formula (13) with diazomethane followed by hydrogenation of the resulting ester.
  • a compound of formula (13) may b converted to a compound of formula (12) by initial lydrogenation followed by esterification with an alcohol RgOH, or diazomethane.
  • pharmaceutically acceptable salts of the compounds of formula (1) may be formed conventionally by reaction with the appropriate acid or base.
  • Solvates may be formed by crystallization from the appropriate solvent.
  • the compounds of formula (1) exist in more than one diastereoisomeric form.
  • the processes of the invention produce mixtures thereof, the individual isomers may be separated one from another by chromatography, e.g. column chromatrography or HPLC.
  • separate diastereoisomeric compounds of formula (1) can be obtained by using stereoisomerically pure starting materials or by separating desired isomers of intermediates at any stage in the overall synthetic process, and converting these intermediates to compounds of formu (1) •
  • the present invention further provides a pharmaceutical composition, which comprises a compound of formula (1) , pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
  • a composition of this invention is useful in the treatme musculo-skeletal disorders, particularly arthritic disea and for modulation of tissue remodelling.
  • a composition of the invention which may be prepared by admixture, may contain a diluent, binder, filler, disintegrant, flavouring agent, colouring agent, lubrica preservative as described in EPA 401963.
  • a composition of the invention may be adapted for oral, topical, rectal or parenteral administration but oral administration is preferred.
  • Parenteral compositions ma administered intravenously, intramuscularly or intra-articularly. The preferred route for administrat will depend upon the disorder for which treatment is required, and is preferably in unit dosage form or in a that a human patient may administer to himself in a singl dosage. Suitable compositions for the compounds of this invention have been described in EPA 401963.
  • the suitable dosage range for the compounds of the invent may vary from compound to compound and may depend on the condition to be treated. It will also depend, inter alia, upon the relation of potency to absorbability and the mode administration chosen.
  • Compositions may, for example, be in the form of tablets, capsules, sachets, vials, powders, granules, lozenges, reconstitutable powders, or liquid preparations, for exampl solutions or suspensions, or suppositories.
  • the preparatio may also be presented as an ointment, cream, lotion, gel, spray, aerosol, wash, skin paint or patch.
  • a unit dose for treating diseases and physiological phenome in which enzymes from the collagenase family are involved will generally contain from 10 to 1000 mg and preferably wi contain from 10 to 500 mg, in particular 10, 50, 100, 150, 200, 250, 300, 350, 400, 450 or 500 mg.
  • the composition ma be administered once or more times a day, for example 2, 3 4 times daily, so that the total daily dose for a 70 kg adu will normally be in the range 10 to 3000 mg.
  • Such a dose corresponds to approximately 0.15 to 50 mg/kg per day.
  • the unit dose will contain from 2 to 20 mg of a compound of the invention and be administered in multiples, if desired, to give the desired daily dose.
  • the present invention additionally provides a method of treating conditions in which degradation of connective tiss and other proteinaceous components of the body occurs, such as rheumatism and/or arthritic conditions in mammals, such humans, which comprises administering to the mammal in need of such treatment an effective amount of a compound of formula (1) or a pharmaceutically acceptable salt thereof.
  • the present invention also provides the use of a compound of formula (1) or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for use in the treatment of conditions in which degradation of connective tissue and other proteinaceous components of the body occurs such as rheumatism and/or arthritic conditions.
  • the aldehyde (D2) (1.8g, 3.88 mmol) was dissolved in ethanol (180 ml) and hydrogenated over 5% palladium-carbon (200 mg) at atmospheric pressure and 35°C for 72h. The suspension was filtered through Kieselguhr and evaporated in vacuo to give crude (S)-3-(N-tert-butoxycarbonyl)amino-1, 8-diazacyclo- tridecan-2-one.
  • the crude amine was dissolved in a mixed solvent system of tetrahydrofuran/water, (6:20 v/v) cooled to 0°C and treated with benzyl chloroformate (0.66g, 3.88 mmol) and excess sodium carbonate to maintain a pH between 10 and 11. The mixture was left stirring at room temperature overnight, washed with ethyl acetate (3x25 ml) , and the combined organic fractions dried over anhydrous magnesium sulphate and evaporated in vacuo to afford a clear oil.
  • the aldehyde (D2) was hydrogenated at about 100 psi over 5% palladium on carbon in methanol, and then in acidic methanol to afford crude (S)-3- (N-tert-butoxycarbonyl) amino-1, 8- diazacyclotridecan-2-one.
  • the amine was treated with benzyl chloroformate and purified as described in Method A to yiel the identical title compound (D3) .
  • This compound was prepared from 3,4-dihydro-3-(2-methyl- propylidene)-2,5-furandione (EPA 274453) by heating in methanol followed by hydrogenation over 10% palladium-carbon in methanol, as a colourless oil.
  • the solution was evaporated to dryness in vacuo, and the residue dissolved in chloroform.
  • the product was chromatographed on silica gel 60 (lOOg) , eluting with ethyl acetate, followed by methanol- ethyl acetate (1:49) to give the title compound as a single diastereoisomer (D8A) (0.22g), as a white solid, m.p. 198- 201°C.
  • the aldehyde (D12) (5.0g) in methanol (450 ml) was treated with 5% palladium-carbon (5.5g) .
  • the suspension was hydrogenated at 140 psi and ambient temperature for 48h, treated with 2.5M aqueous hydrochloric acid (3 ml) and hydrogenation continued at the said pressure for a further 24h.
  • the suspension was filtered through Kieselguhr and evaporated in vacuo to give crude (S)-3-(N-tert- butoxycarbonyl)amino-1, 8-diazacyclotetradecan-2-one.
  • Methyl 3-(R)-(tert-butoxycarbonyl)-2-(S)-methyl-5-methyl hexanoate (D10) (lg) was added to 5% aqueous trifluoroacetic acid (15 ml) at 0°C and the solution was stirred at 0°C for 8h and then evaporated to dryness in vacuo.
  • the resulting carboxylic acid was dissolved in dichloromethane (20 ml) , cooled to 0°C, and then the solution was treated with 1- ethyl-3-[3-(dimethylamino)propyl]carbodiimide hydrochlorid (0.74g) and l-hydroxybenzotriazole (0.52g).
  • the title compound was prepared as a mixture of diastereoisomers from (S)-N-[3-(S)-methoxycarbonyl-2- (R)- ( methylpropyl)butanoyl]amino-8-(N-benzyloxycarbonyl)-1, 8- diazacyclotetradecan-2-one (D15) by the procedure describe for (D7) .
  • diastereomeric mixture (D17) can be separated into individu diastereomers D17A, Rf (chloroform/methanol 9:1) 0.3 follow by diastereomer D17B, Rf (chloroform/methanol 9:1) 0.26, by column chromatography on silica gel with initially 2% methanol/chloroform as eluent, rising to 5% methanol/chloroform.
  • compositions for oral administration may be prepared by combining the following:
  • the mixture may be compressed to tablets, or filled into har gelatin capsules.
  • the tablet may be coated by applying a suspension of film former (e.g. HPM cellulose), pigment (e.g. titanium dioxide) and plasticiser (e.g. diethyl phthalate) and drying the film by evaporation of the solvent.
  • film former e.g. HPM cellulose
  • pigment e.g. titanium dioxide
  • plasticiser e.g. diethyl phthalate
  • the film coat can comprise 2.0% to 6.0% of the tablet weight, preferably about 3.0%.
  • the medicinal compound is dispersed or dissolved in the liquid carrier, with a thickening agent added, if required.
  • the formulation is then enclosed in a soft gelatin capsule b suitable technology.
  • a pharmaceutical composition for parenteral administration may be prepared by combining the following:
  • the solution is sterilised and sealed in sterile containers
  • test is performed essentially as in Cawston and Barre Anal. Biochem. 99, 340-345 (1979).
  • Compounds for testin are dissolved in methanol by sonication and added to collagenase (purified from culture supernatants from the human lung fibroblast cell line, WI-38) in buffer.
  • Afte 5 in pre-incubation at 37°C, the assay tubes are cooled t 4°C and ⁇ H-acetylated rat skin type I collagen is added.
  • the assay tubes are incubated at 37°C overnight.
  • the 3 H- collagen forms insoluble fibrils, which are the substrate the enzyme.
  • the assay tubes are spun at 12000 for 15 minutes. Undigested ⁇ H-collagen . s pelleted, whi digested ⁇ -collagen is found as soluble peptides in the supernatant. A sample of the supernatant is taken for liquid scintillation counting.
  • IC50 50% inhibit concentration
  • the compounds of Examples 1 and 2 had IC5Q values in the range 8xl0 "7 - 8xl0 _9 M.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention se rapporte à des dérivé d'acide hydroxamique destinés à servir de médicaments et représentés par la formule (1), ou à un sel, un solvate ou un hydrate de ces dérivés. Dans la formule (1), R1 représente hydrogène, alkyle C1-6, ou -(CH2)n-A-R4, où n est compris entre 0 et 6, A représente une liaison ou un hétéroatome d'oxygène ou de souffre et R4 représente un aryle éventuellement substitué ou un groupe hétéroaryle éventuellement substitué; R2 représente alkyle C3-6; et R3 représente -(CH2)p-X-(CH2)q-, où p représente un nombre entier compris entre 1 et 9, q représente un nombre entier compris entre 2 et 10, et la fraction -(CH2)p- est adjacente à l'atome de carbone marqué d'un astérisque dans la formule (1), et X représente -NR5- où R5 est choisi parmi hydrogène, alkyle C1-6, alcanoyle C2-6, alcoxycarbonyle C1-6 et aryle, aralkyle ou aralkyloxycarbonyle, dans chacun desquels la fraction aryle est éventuellement substituée.
EP92907701A 1991-04-08 1992-04-06 Nouveaux composes Withdrawn EP0579650A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919107368A GB9107368D0 (en) 1991-04-08 1991-04-08 Novel compounds
GB9107368 1991-04-08

Publications (1)

Publication Number Publication Date
EP0579650A1 true EP0579650A1 (fr) 1994-01-26

Family

ID=10692843

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92907701A Withdrawn EP0579650A1 (fr) 1991-04-08 1992-04-06 Nouveaux composes

Country Status (4)

Country Link
EP (1) EP0579650A1 (fr)
JP (1) JPH06505989A (fr)
GB (1) GB9107368D0 (fr)
WO (1) WO1992017460A1 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5594006A (en) * 1993-03-18 1997-01-14 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives as matrix metalloproteinases inhibitors
CA2136108A1 (fr) * 1993-03-18 1994-09-29 Makoto Sakamoto Utilisation de derives de carbostyryle comme inhibiteurs des metalloproteinases matricielles
UA43358C2 (uk) * 1994-01-20 2001-12-17 Брітіш Біотек Фармасьютікелз Лімітед Інгібітори металопротеіназ, спосіб їх отримання (варіанти), спосіб лікування, спосіб отримання засобу для лікування та фармацевтична композиція
GB9423914D0 (en) * 1994-11-26 1995-01-11 British Biotech Pharm Polyether derivatives as metalloproteinase inhibitors
US5639746A (en) * 1994-12-29 1997-06-17 The Procter & Gamble Company Hydroxamic acid-containing inhibitors of matrix metalloproteases
US5919940A (en) * 1995-01-20 1999-07-06 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
US5672598A (en) * 1995-03-21 1997-09-30 The Procter & Gamble Company Lactam-containing hydroxamic acids
US5917090A (en) * 1995-06-30 1999-06-29 British Biotech Pharmaceuticals Ltd. Matrix metalloproteinase inhibitors
CZ292617B6 (cs) 1995-11-23 2003-11-12 British Biotech Pharmaceuticals Limited Inhibitory metaloproteinázy a farmaceutický prostředek
EP0925303B1 (fr) * 1996-08-28 2002-10-23 The Procter & Gamble Company Amides d'acide phosphinique utilises comme inhibiteurs de metalloproteases de matrices
KR20000035918A (ko) * 1996-08-28 2000-06-26 데이비드 엠 모이어 1,3-디헤테로시클릭 메탈로프로테아제 저해제
KR20000035917A (ko) * 1996-08-28 2000-06-26 데이비드 엠 모이어 1,4-헤테로고리성 메탈로프로테아제 저해제
KR20000035920A (ko) * 1996-08-28 2000-06-26 데이비드 엠 모이어 헤테로고리성 메탈로프로테아제 저해제
PT927183E (pt) * 1996-08-28 2004-12-31 Procter & Gamble Inibidores espirociclicos de metaloproteases
US6462023B1 (en) 1996-09-10 2002-10-08 British Biotech Pharmaceuticals, Ltd. Cytostatic agents
BR9712019A (pt) 1996-09-10 1999-08-24 British Biotech Pharm Derivados de cidos hirox-mico citoest ticos
IL134273A0 (en) 1997-07-31 2001-04-30 Procter & Gamble Acyclic metalloprotease inhibitors
US6329418B1 (en) 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
HRP990246A2 (en) 1998-08-07 2000-06-30 Du Pont Pharm Co Succinoylamino benzodiazepines as inhibitors of a beta protein production
NZ525513A (en) 1998-08-07 2004-09-24 Pont Pharmaceuticals Du Succinoylamino lactams as inhibitors of Abeta protein production
EP1313426A2 (fr) 1998-12-24 2003-05-28 Bristol-Myers Squibb Pharma Company Benzodiazepines succinoylamino utilisees comme inhibiteurs de la production de proteine a-beta
US6566381B1 (en) 1999-03-03 2003-05-20 The Procter & Gamble Company Hetero-substituted metalloprotease inhibitors
WO2000051975A1 (fr) 1999-03-03 2000-09-08 The Procter & Gamble Company Inhibiteurs de metalloproteases, contenant alcenyle et alcynale
US6696456B1 (en) 1999-10-14 2004-02-24 The Procter & Gamble Company Beta disubstituted metalloprotease inhibitors
US6525044B2 (en) 2000-02-17 2003-02-25 Bristol-Myers Squibb Company Succinoylamino carbocycles and heterocycles as inhibitors of a-β protein production
PL365444A1 (en) 2000-03-21 2005-01-10 The Procter & Gamble Company Heterocyclic side chain containing, n-substituted metalloprotease inhibitors
AU2001245862A1 (en) 2000-03-21 2001-10-03 The Procter & Gamble Company Difluorobutyric acid metalloprotease inhibitors
US6495540B2 (en) 2000-03-28 2002-12-17 Bristol - Myers Squibb Pharma Company Lactams as inhibitors of A-β protein production
BR0107532A (pt) 2000-04-03 2004-11-03 Bristol Myers Squibb Pharma Co Composto, uso do composto, método para o tratamento de disfunções neurológicas associadas com a produção de b-amilóide, método de inibição da atividade de y-secretase e composição farmacêutica
CA2403550A1 (fr) 2000-04-03 2001-10-11 Hong Liu Lactames cycliques utiles en tant qu'inhibiteurs de la production de proteine a-beta
BR0106717A (pt) 2000-06-01 2002-04-16 Bristol Myers Squibb Pharma Co Compostos, composição farmacêutica e usos dos compostos de lactama inovadora

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CY1406A (en) * 1980-12-18 1988-04-22 Schering Corp Substituted dipeptides, processes for their preparation and pharmaceutical compositions containing them and their use in the inhibition of enkephalinase
EP0401963A1 (fr) * 1989-04-13 1990-12-12 Beecham Group p.l.c. Phosphonopeptides avec activité inhibitrice de collagénase
GB9000846D0 (en) * 1990-01-15 1990-03-14 Beecham Group Plc Novel compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9217460A1 *

Also Published As

Publication number Publication date
GB9107368D0 (en) 1991-05-22
WO1992017460A1 (fr) 1992-10-15
JPH06505989A (ja) 1994-07-07

Similar Documents

Publication Publication Date Title
EP0579650A1 (fr) Nouveaux composes
JP2768554B2 (ja) 金属タンパク質加水分解酵素阻害剤であるヒドロキサム酸誘導体
EP0498665B1 (fr) Dérivés de l'acide hydroxamique, procédé pour leur préparation et leur utilisation
DE69621830T2 (de) Alpha-substituierte arylsulphonamidohydroxamsaüre als tnf-alpha und matrix-metalloproteinase-inhibitoren
JP2706646B2 (ja) カルボキシアルキルペプチド誘導体
JPS61263998A (ja) 新規なｎ−（アシルジペプチジル）−アミノグリコ−ル化合物
JPH0437070B2 (fr)
EP0434365A2 (fr) Inhibiteurs de la HIV protéase utilisable dans le traitement du SIDA
MXPA98001093A (en) Inhibitors of proteinase c for the treatment of diseases related to the overproduction of colag
EP0859784B1 (fr) Peptides thio-substitues utiles comme inhibiteurs de metalloproteases et de la liberation du tnf
BG65755B1 (bg) Инхибитори на клетъчна адхезия
AU2017326611A1 (en) YAP1 inhibitors that target the interaction of YAP1 with Oct4
JPS6323897A (ja) タフトシン類似体、その製法及び医薬組成物
NZ240167A (en) Heterocyclically substituted thiol amide derivatives; medicaments, preparation, and use thereof
AU634383B2 (en) Phosphonopeptides with collagenase inhibiting activity
EP1806141B1 (fr) Antagonistes des récepteurs de type par-2
JPH05155847A (ja) アミノ酸誘導体及びその医薬品としての利用
HU206194B (en) Process for producing cyclomethylene-1,2-dicarboxylic acid derivatives and pharmaceutical compositions comprising same
EP0513016A1 (fr) Agents diuretiques a base de glutaramide a substitution cycloalkyle
US5416119A (en) Alkylaminoalkyl-terminated sulfide/sulfonyl-containing cycloalkyl-alanine amino-diol compounds for treatment of hypertension
JPH0532602A (ja) ナフチルメチルアミン誘導体及びこれを含有するレニン阻害剤
EP0655063B1 (fr) Composes aminodiols d'alanine d'ethynyle comprenant un groupe a terminaison piperazinyle ou un groupe a terminaison piperazinyle-alkylamino, destines au traitement de l'hypertension
JPH068268B2 (ja) 新規ペプチド及びその製造方法
JP2002541254A (ja) トロンビンインヒビターのプロドラッグ
JPH03204860A (ja) レニン阻害活性を有する新規アミノ酸誘導体

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19930903

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE FR GB IT LI NL

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19951103